Van Baak M A
Department of Pharmacology, University of Limburg.
Sports Med. 1988 Apr;5(4):209-25. doi: 10.2165/00007256-198805040-00002.
Blockade of beta-adrenoceptors interferes with haemodynamic and metabolic adaptations and ion balance during dynamic exercise. After administration of a beta-blocker exercise heart rate is reduced. Exercise cardiac output and blood pressure are reduced also, but to a lesser extent than heart rate. At submaximal exercise intensities blood flow to the active skeletal muscle is also reduced. The availability of non-esterified fatty acids for energy production is decreased, due to inhibition of beta-adrenoceptor-mediated adipose tissue lipolysis, and possibly also of intramuscular triglyceride breakdown. During submaximal exercise muscle glycogenolysis is unaffected, but there are indications that the maximal glycogenolytic rate at high exercise intensities is decreased. In normally fed subjects plasma glucose concentration is maintained at a normal level during submaximal endurance exercise after beta-blocker administration, although lower glucose concentrations are found in fasting subjects and during high intensity exercise after beta-blocker administration. Plasma lactate concentrations tend to be somewhat lower after beta-blocker administration while plasma potassium concentration during exercise is increased. beta-Blocker administration may also interfere with thermoregulation during prolonged exercise. Maximal aerobic exercise capacity is reduced in normotensive and probably also in hypertensive subjects after beta-blocker administration. Submaximal endurance performance is impaired to a much more important extent in both groups of subjects. In patients with coronary artery disease, on the other hand, symptom-limited exercise capacity is improved during beta-blocker treatment. Studies on trainability during beta-blocker treatment show inconsistent results in healthy subjects, although the majority of studies suggest a similar training-induced increase in VO2max during placebo and beta-blocker treatment. In patients with coronary artery disease the training effects are also similar in patients treated with beta-blockers and those without. The negative effects of beta-blockers on maximal and especially submaximal exercise capacity should be considered when prescribing beta-blockers to physically active hypertensive patients. The negative influence is shared by all types of beta-blockers, although the impairment of submaximal exercise capacity is more pronounced with non-selective than with beta 1-selective beta-blockers. beta-Blockers with intrinsic sympathomimetic activity have similar effects during exercise to those without intrinsic sympathomimetic activity.
β-肾上腺素能受体阻滞剂会干扰动态运动期间的血流动力学和代谢适应以及离子平衡。服用β-阻滞剂后,运动心率会降低。运动心输出量和血压也会降低,但降低程度小于心率。在次最大运动强度时,流向活跃骨骼肌的血流量也会减少。由于β-肾上腺素能受体介导的脂肪组织脂解受到抑制,并且肌肉内甘油三酯分解可能也受到抑制,用于能量产生的非酯化脂肪酸的可用性降低。在次最大运动期间,肌肉糖原分解不受影响,但有迹象表明,在高运动强度下最大糖原分解速率会降低。在正常进食的受试者中,服用β-阻滞剂后进行次最大耐力运动时,血浆葡萄糖浓度维持在正常水平,尽管在空腹受试者以及服用β-阻滞剂后进行高强度运动时发现葡萄糖浓度较低。服用β-阻滞剂后血浆乳酸浓度往往会略低,而运动期间血浆钾浓度会升高。服用β-阻滞剂也可能会干扰长时间运动期间的体温调节。服用β-阻滞剂后,正常血压受试者以及可能高血压受试者的最大有氧运动能力都会降低。两组受试者的次最大耐力表现受损程度更为严重。另一方面,在冠状动脉疾病患者中,β-阻滞剂治疗期间症状限制运动能力会得到改善。关于β-阻滞剂治疗期间可训练性的研究在健康受试者中结果不一致,尽管大多数研究表明,安慰剂和β-阻滞剂治疗期间训练引起的最大摄氧量增加相似。在冠状动脉疾病患者中,服用β-阻滞剂的患者和未服用β-阻滞剂的患者的训练效果也相似。在为身体活跃的高血压患者开β-阻滞剂处方时,应考虑β-阻滞剂对最大运动能力尤其是次最大运动能力的负面影响。所有类型的β-阻滞剂都会产生负面影响,尽管非选择性β-阻滞剂比β1选择性β-阻滞剂对次最大运动能力的损害更明显。具有内在拟交感活性的β-阻滞剂在运动期间的作用与没有内在拟交感活性的β-阻滞剂相似。